Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.

Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L.

Invest New Drugs. 2015 Apr;33(2):321-31. doi: 10.1007/s10637-014-0171-9. Epub 2014 Nov 8.

PMID:
25380635
2.

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.

Rathkopf D, Liu G, Carducci MA, Eisenberger MA, Anand A, Morris MJ, Slovin SF, Sasaki Y, Takahashi S, Ozono S, Fung NK, Cheng S, Gan J, Gottardis M, Obermeier MT, Reddy J, Zhang S, Vakkalagadda BJ, Alland L, Wilding G, Scher HI; Prostate Cancer Clinical Trials Consortium.

Clin Cancer Res. 2011 Feb 15;17(4):880-7. doi: 10.1158/1078-0432.CCR-10-2955. Epub 2010 Dec 3.

3.

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP.

Invest New Drugs. 2011 Dec;29(6):1426-31. doi: 10.1007/s10637-010-9498-z. Epub 2010 Aug 3.

PMID:
20680660
4.

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG.

N Engl J Med. 2006 Jun 15;354(24):2542-51.

5.

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.

Verstovsek S, Golemovic M, Kantarjian H, Manshouri T, Estrov Z, Manley P, Sun T, Arlinghaus RB, Alland L, Dugan M, Cortes J, Giles F, Beran M.

Cancer. 2005 Sep 15;104(6):1230-6.

6.

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.

Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M.

Clin Cancer Res. 2005 Jul 1;11(13):4941-7.

7.

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C.

J Clin Oncol. 2004 Oct 1;22(19):3893-901.

PMID:
15459210
8.

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group.

Ann Oncol. 2004 Mar;15(3):440-9.

PMID:
14998846
9.

Identification of mammalian Sds3 as an integral component of the Sin3/histone deacetylase corepressor complex.

Alland L, David G, Shen-Li H, Potes J, Muhle R, Lee HC, Hou H Jr, Chen K, DePinho RA.

Mol Cell Biol. 2002 Apr;22(8):2743-50.

10.

Gene-target recognition among members of the myc superfamily and implications for oncogenesis.

O'Hagan RC, Schreiber-Agus N, Chen K, David G, Engelman JA, Schwab R, Alland L, Thomson C, Ronning DR, Sacchettini JC, Meltzer P, DePinho RA.

Nat Genet. 2000 Feb;24(2):113-9.

PMID:
10655054
11.

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.

David G, Alland L, Hong SH, Wong CW, DePinho RA, Dejean A.

Oncogene. 1998 May 14;16(19):2549-56.

12.

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

Pomerantz J, Schreiber-Agus N, LiƩgeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA.

Cell. 1998 Mar 20;92(6):713-23.

13.

Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.

Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N, DePinho RA.

Nature. 1997 May 1;387(6628):49-55.

PMID:
9139821
14.

A biochemical and biological analysis of Myc superfamily interactions.

Schreiber-Agus N, Alland L, Muhle R, Goltz J, Chen K, Stevens L, Stein D, DePinho RA.

Curr Top Microbiol Immunol. 1997;224:159-68. Review. No abstract available.

PMID:
9308239
15.

Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.

Rao G, Alland L, Guida P, Schreiber-Agus N, Chen K, Chin L, Rochelle JM, Seldin MF, Skoultchi AI, DePinho RA.

Oncogene. 1996 Mar 7;12(5):1165-72.

PMID:
8649810
16.

Rapid high-resolution western blotting.

Okamura H, Sigal CT, Alland L, Resh MD.

Methods Enzymol. 1995;254:535-50. No abstract available.

PMID:
8531713
17.

Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization.

Alland L, Peseckis SM, Atherton RE, Berthiaume L, Resh MD.

J Biol Chem. 1994 Jun 17;269(24):16701-5.

Supplemental Content

Loading ...
Support Center